Journal article

Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety

Catherine Glover, Nigel Crawford, Alan Leeb, Nicholas Wood, Kristine Macartney

VACCINE | ELSEVIER SCI LTD | Published : 2020


BACKGROUND: Maternal immunisation is important to protect both mother and baby, but safety concerns can lead to low uptake. AusVaxSafety participant-based surveillance actively monitors adverse events following immunisation (AEFI) in Australia. We aimed to analyse AEFI in the days following vaccination with seasonal inactivated influenza vaccine (IIV) and/or reduced antigen diphtheria-tetanus-acellular pertussis vaccine (dTpa) in pregnant women in Australia. METHODS: De-identified AEFI reports were solicited from vaccine recipients via automated SMS survey (using SmartVax software) following routine vaccination with IIV and/or dTpa at 219 national sentinel surveillance sites from 2015 to 201..

View full abstract


Funding Acknowledgements

We would like to thank AusVaxSafety Expert Leadership Group members Chris Blyth, Jim Buttery, David Durrheim, Paul Effler, Mike Gold, and Tom Snelling, as well as NCIRS colleagues Helen Quinn, Alexis Pillsbury, Chloe Damon, Nicola Carter, and Heidi Williams, for their contributions to AusVaxSafety surveillance. We would also like to thank Ian Peters and Karin Orlemann for their work on SmartVax. We would like to thank staff at participating sentinel immunisation provider sites, and especially the vaccine recipients who participated in this surveillance. The AusVaxSafety surveillance system is funded by the Australian Government Department of Health and administered under a contract with the Australian National Centre for Immunisation Research and Surveillance (NCIRS).